SKYESkye Bioscience, Inc.vs its industry peers
A metric-by-metric comparison of Skye Bioscience, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SKYE본 종목 | $47M#8 | — | — | — | — | -110.5%#9 | — | — | — | — | — | — |
| CLNN | $50M#1 | — | — | 250.2x#2 | -41.5%#2 | 33.6%#2 | -11541.5%#2 | — | — | — | -60.5%#2 | — |
| GANX | $50M#2 | — | 4.4x#5 | 897.7x#5 | -58.4%#3 | 1.2%#5 | -33908.5%#3 | -178.5%#5 | — | — | -35.5%#1 | — |
| IBIO | $48M#3 | — | 0.6x#1 | 484.6x#3 | -75.0%#4 | -78.7%#8 | -35141.0%#4 | -38.3%#1 | — | — | — | — |
| ANVS | $48M#4 | — | — | — | — | -17.3%#6 | — | — | — | — | — | — |
| HOWL | $48M#5 | — | 2.9x#4 | — | — | 13.7%#3 | — | -373.3%#6 | -229.9%#1 | — | — | — |
| ATNM | $47M#6 | 4.3x#1 | 1.5x#3 | 520.5x#4 | — | 11.4%#4 | -40274.4%#5 | -111.8%#3 | — | — | — | — |
| AZTR | $47M#7 | 38.6x#2 | 6.4x#6 | — | -100.0%#5 | -22.2%#7 | — | -149.4%#4 | — | — | — | — |
| XLO | $46M#9 | — | 0.6x#2 | 1.1x#1 | 589.9%#1 | 39.8%#1 | -95.9%#1 | -48.5%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice